Yat Sun Or
Chief Scientific Officer @Enanta Pharmaceuticals
Signup · Get unlimited contacts
WORK HISTORY
Chief Scientific Officer @Enanta Pharmaceuticals
Senior VP R&D, and Chief Scientific Officer at Enanta PharmaceuticalsResponsible for the startup team building and comprehensive drug discovery programs from conception to human clinical studies for compounds (EDP-420, EDP-322, EDP-788, EDP-239, and EDP-494), and to the market through research collaboration with AbbVie (ABT-450 and ABT-493), as well as a key team member leading Enanta to IPO.Key Contributions:· Assembly of a a research team with scientific excellence at Enanta Pharmaceuticals· Supervise directors of research in medicinal chemistry, patent estate, molecular biology, and pharmacology· Oversight of drug development including CMC, IND filing, Ph1 and Ph2 antibacterial clinical trials · Established core competence in infectious diseases including antibacterial, hepatitis C, hepatitis B, and respiratory syncytial virus (RSV) infections· Initiated nuclear receptor FXR agonist for the treatment of non-alcoholic steatohepatitis (nash); established broad patent estate and advanced compounds to IND filing
EDUCATION
University of Chicago
Ph.D, Chemistry
ABOUT YAT SUN OR
Diligent, motivated entrepreneur with extensive industrial experience in drug discovery and development. Strong organizational, technical, and interpersonal skill. Key demonstrated skills and accomplishments include:· Recruitment and leadership of senior staff, and R&D team building· Drug discovery from conception to patent estate, and execution of early phase clinical studies· CRO selection and monitoring for chemistry, DMPK, toxicology, and investigational studies· Technology/product evaluation and licensing negotiations· Alliance management ABT-Ligand ABT-Taisho Enanta-Shionogi Enanta-AbbVie Enanta-Novartis Enanta-NIAID· Drug candidates ABT-450 (Paritaprevir) HCV Marketed ABT-493 (Grecaprevir) HCV 8 ongoing Ph3 clinical trials ABT-773 (Cethromycin) Antibacterial NDA ABT-281 Psoriasis Ph3 EDP-420 (Modithromycin) Antibacterial Ph2 EDP-322 MRSA Ph1 completion EDP-239 (NS5A inhibitor) HCV Ph1 and PoC completion EDP-494 (Cyclophilin In) HCV Ph1 ongoing
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.